Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.

作者信息

Calabresi P A, Fields N S, Maloni H W, Hanham A, Carlino J, Moore J, Levin M C, Dhib-Jalbut S, Tranquill L R, Austin H, McFarland H F, Racke M K

机构信息

Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.

出版信息

Neurology. 1998 Jul;51(1):289-92. doi: 10.1212/wnl.51.1.289.

DOI:10.1212/wnl.51.1.289

PMID:9674825

Abstract

Transforming growth factor (TGF)-beta2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.

摘要